Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

methotrexate

8 abstracts

Abstract
CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.
Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,
Abstract
A phase III randomized, open-label study to establish the superiority of triple oral metronomic therapy (OMCT) used in addition to chemotherapy regimen (paclitaxel + carboplatin) over chemotherapy alone for the treatment of advanced unresectable head and neck cancer squamous cell cancer (HNSCC).
Org: Mahamana Pandit Madan Mohan Malviya Cancer Centre & Homi Bhabha Cancer Hospital, Varanasi, India, Varanasi, Uttar Pradesh, India, Mumbai, India,
Abstract
Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC).
Org: PRECISIONheor,
Abstract
A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.
Org: Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia, University of Florida Department of Biostatistics, UCSF Benioff Children's Hospital Oakland, Loyola University Medical Center,
Abstract
Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.
Org: La Roche-Posay International, Levallois-Perret, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, Memorial Sloan Kettering Cancer Center,
Abstract
High dose methotrexate (MTX) treatment: Value of post treatment MTX level monitoring and risk factors for acute kidney injury.
Org: Maimonides Medical Center, Brooklyn, NY, Maimonides Cancer Center,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA,